Although the selective blockade of IL-6 trans-signaling with sgp130Fc is known to attenuate atrial fibrillation (AF) inducibility in transverse aortic constriction-challenged mice [141], the potential therapeutic benefits and efficacy of selectively targeting IL-6 trans-signaling (olamkicept) for the prevention of ventricular arrhythmias, particularly in obesity, are unknown, which further provides the rationale to refine olamkicept for the development of the next generation of inhibitors of IL-6 trans-signaling as an anti-arrhythmic target. Here, IL6 is linked to obesity disorder.